Hepsera adefovir dipivoxil: Phase III data; marketed in U.S

In a double-blind, placebo-controlled, international Phase III trial (Study 438), 96-week data showed 71% (50/70) of Hepsera patients had undetectable levels of serum HBV DNA (less than 1,000 copies/m...